Skip to content

Study · In vitro (cells) · pseudomonas aeruginosa · 2021

6 results

Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates.

Díez-Aguilar M, Hernández-García M, Morosini MI, Fluit A, Tunney MM, Huertas N, Del Campo R, Obrecht D, Bernardini F, Ekkelenkamp M, Cantón R

The Journal of antimicrobial chemotherapy1 Mar 2021Cited by 47 (Europe PMC)

PMID33367642 (opens in a new tab)DOI10.1093/jac/dkaa529 (opens in a new tab)PepBankPUB-33367642
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In CF isolates, murepavadin MIC50 was 0.125 mg/L by broth microdilution versus 4 mg/L by agar dilution.

    In plain wordsIn lab tests, murepavadin MIC50 was 0.125 mg/L by broth testing versus 4 mg/L by agar testing.

    Peptide
    Murepavadin
    Outcome
    Not applicableMIC50 by assay method
    Study

    Pseudomonas aeruginosan: not reported in source

    Cystic fibrosis isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MIC50
    0.125 mg/L
    broth microdilution
    MIC50
    4 mg/L
    agar dilution

    Source sentences

    Summary
    The murepavadin MIC50 was 0.125 versus 4 mg/L and the MIC90 was 2 versus 32 mg/L by broth microdilution and agar dilution, respectively.
    1 context sentence
    Summary · context
    To determine the in vitro activity of murepavadin against CF P. aeruginosa isolates and to investigate potential mechanisms of resistance.
  2. 02LabIn vitro (cells)Activity measurement

    In CF isolates, murepavadin MIC90 was 2 mg/L by broth microdilution versus 32 mg/L by agar dilution.

    In plain wordsIn lab tests, murepavadin MIC90 was 2 mg/L by broth testing versus 32 mg/L by agar testing.

    Peptide
    Murepavadin
    Outcome
    Not applicableMIC90 by assay method
    Study

    Pseudomonas aeruginosan: not reported in source

    Cystic fibrosis isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Measurements

    MIC90
    2 mg/L
    broth microdilution
    MIC90
    32 mg/L
    agar dilution

    Source sentences

    Summary
    The murepavadin MIC50 was 0.125 versus 4 mg/L and the MIC90 was 2 versus 32 mg/L by broth microdilution and agar dilution, respectively.
    1 context sentence
    Summary · context
    To determine the in vitro activity of murepavadin against CF P. aeruginosa isolates and to investigate potential mechanisms of resistance.
  3. 03LabIn vitro (cells)Activity measurement

    In vitro, murepavadin activity showed >90% essential agreement with artificial sputum or lung surfactant.

    In plain wordsIn lab tests, murepavadin activity showed >90% essential agreement with artificial sputum or lung surfactant.

    Peptide
    Murepavadin
    Outcome
    Not applicableActivity agreement with sputum or surfactant
    Study

    Pseudomonas aeruginosan: not reported in source

    Cystic fibrosis isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Essential agreement was >90% when determining in vitro activity with artificial sputum or lung surfactant.
    1 context sentence
    Summary · context
    To determine the in vitro activity of murepavadin against CF P. aeruginosa isolates and to investigate potential mechanisms of resistance.
  4. 04LabIn vitro (cells)Activity measurement

    In vitro, murepavadin at 32 mg/L was bactericidal against 95.4% of strains within 1-5 h.

    In plain wordsIn lab tests, murepavadin at 32 mg/L killed bacteria in 95.4% of strains within 1-5 h.

    Peptide
    Murepavadin
    Outcome
    DecreaseBactericidal activity
    Study

    Pseudomonas aeruginosan: not reported in source

    Cystic fibrosis isolates
    Outcome group
    Infection and antimicrobial activity · Infection
    Studied dose
    32 mg/L · 1-5 hAs given in this study (Pseudomonas aeruginosa).

    Source sentences

    Summary
    It was bactericidal at a concentration of 32 mg/L against 95.4% of the strains within 1-5 h.
    1 context sentence
    Summary · context
    To determine the in vitro activity of murepavadin against CF P. aeruginosa isolates and to investigate potential mechanisms of resistance.

Studies that did not test the peptide alone2

In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Murepavadin.

  1. 05LabNot a test of Murepavadin aloneIn vitro (cells)Activity measurement

    In mutant derivatives, murepavadin MICs were 2-9 two-fold dilutions higher than in parental strains.

    In plain wordsIn lab tests, mutants had higher murepavadin MICs than parental strains.

    Peptide
    Murepavadin
    Outcome
    IncreaseMutant MIC elevation
    Study

    Pseudomonas aeruginosan: not reported in source

    Cystic fibrosis isolates
    Comparator
    Parental strains
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Murepavadin MICs were 2-9 two-fold dilutions higher for the mutant derivatives (0.5 to >16 mg/L) than for the parental strains.
    1 context sentence
    Summary · context
    To determine the in vitro activity of murepavadin against CF P. aeruginosa isolates and to investigate potential mechanisms of resistance.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

  2. 06LabNot a test of Murepavadin aloneIn vitro (cells)Activity measurement

    In PAO mutS second-step mutants, murepavadin MIC increased 8-fold.

    In plain wordsIn lab tests, PAO mutS second-step mutants showed an 8-fold murepavadin MIC increase.

    Peptide
    Murepavadin
    Outcome
    IncreaseSecond-step mutant MIC elevation
    Study

    Pseudomonas aeruginosan: not reported in source

    PAO mutS second-step mutants
    Outcome group
    Infection and antimicrobial activity · Infection

    Source sentences

    Summary
    Second-step mutants were obtained for the PAO mutS reference strain with an 8×MIC increase.
    1 context sentence
    Summary · context
    To determine the in vitro activity of murepavadin against CF P. aeruginosa isolates and to investigate potential mechanisms of resistance.

    In this study, Murepavadin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Murepavadin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.